1
WGU D116 Advanced Pharmacology Final Exam
Actual Exam 2026/2027 – Complete Exam-Style
Questions with Detailed Rationales | 100%
Verified | Pass Guaranteed – A+ Graded
[SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS]
1. Which route of administration is most affected by the first-pass effect, resulting in
significantly lower bioavailability of the drug?
A. Sublingual.
B. Intravenous.
C. Oral.
D. Transdermal.
Correct Answer: C
Rationale: Oral administration exposes drugs to the acidic environment of the stomach and the
hepatic portal system before they reach systemic circulation. This "first-pass metabolism" by the
liver metabolizes a significant portion of the drug, lowering the bioavailability. Intravenous (B)
bypasses this entirely, and sublingual (A) and transdermal (D) routes enter the systemic
circulation directly via capillaries, avoiding significant first-pass metabolism.
2. A drug with a high volume of distribution (Vd) is most likely to have which characteristic?
A. Low concentration in tissues.
B. High concentration in plasma.
C. Extensive distribution into body tissues.
D. Low lipid solubility.
Correct Answer: C
Rationale: Volume of distribution (Vd) is a theoretical volume that relates the amount of drug in
the body to its plasma concentration. A high Vd indicates that the drug is extensively distributed
,2
into body tissues (often due to high lipid solubility) rather than remaining in the plasma. Drugs
with high Vd are often highly protein-bound and lipophilic.
3. A patient taking a highly protein-bound drug (e.g., warfarin) is prescribed a second drug that
displaces it from albumin. What is the clinical result?
A. Increased free drug concentration and risk of toxicity.
B. Decreased free drug concentration and risk of subtherapeutic effect.
C. Increased metabolism of the drug by the liver.
D. Rapid elimination by the kidneys.
Correct Answer: A
Rationale: Protein-bound drugs exist in equilibrium with free (active) drug. If a second drug
displaces the first from binding sites (e.g., albumin), the concentration of free, pharmacologically
active drug increases suddenly. This can lead to toxicity, as the body is suddenly exposed to a
higher level of active drug.
4. Which Cytochrome P450 (CYP) enzyme is responsible for the metabolism of the largest
percentage of drugs?
A. CYP2D6.
B. CYP3A4.
C. CYP2C9.
D. CYP1A2.
Correct Answer: B
Rationale: CYP3A4 is the most abundant CYP enzyme in the liver and is responsible for
metabolizing approximately 50% of currently available drugs. It is also highly susceptible to
induction (by St. John's Wort) and inhibition (by grapefruit juice), leading to significant drug
interactions.
,3
5. A patient is taking theophylline for COPD. They start taking ciprofloxacin, a CYP1A2
inhibitor. What adjustment is needed?
A. Increase theophylline dose.
B. Decrease theophylline dose.
C. No change needed.
D. Switch to inhaled corticosteroids.
Correct Answer: B
Rationale: Theophylline is primarily metabolized by CYP1A2. Ciprofloxacin is a strong
CYP1A2 inhibitor, which will decrease the clearance of theophylline, leading to elevated serum
levels and potential toxicity (nausea, seizures). Therefore, the dose of theophylline must be
decreased to prevent toxicity.
6. Which drug has the narrowest therapeutic index, requiring careful monitoring to avoid
toxicity?
A. Penicillin VK.
B. Amlodipine.
C. Digoxin.
D. Ibuprofen.
Correct Answer: C
Rationale: Digoxin has a narrow therapeutic index, meaning the difference between a therapeutic
dose and a toxic dose is very small. Small increases in serum levels can lead to life-threatening
arrhythmias or visual changes, necessitating close monitoring of serum digoxin levels. Penicillin
(A) and ibuprofen (D) have wide safety margins.
7. A partial agonist differs from a full agonist in that a partial agonist:
A. Has higher efficacy than a full agonist.
B. Binds to the same receptor but produces a submaximal response.
C. Binds to a different receptor site.
, 4
D. Produces a response only in the presence of an endogenous ligand.
Correct Answer: B
Rationale: A partial agonist binds to the same receptor as a full agonist but has lower intrinsic
efficacy. Even at full receptor occupancy, it cannot produce the maximal response (Emax) that a
full agonist can, effectively acting as an antagonist in the presence of a full agonist.
8. Which Phase I reaction involves oxidative reactions (oxidation, reduction, hydrolysis)
primarily mediated by CYP450 enzymes?
A. Glucuronidation.
B. Acetylation.
C. Sulfation.
D. Oxidation.
Correct Answer: D
Rationale: Phase I reactions modify the drug chemically through oxidation, reduction, or
hydrolysis to expose or add a functional group, making it more hydrophilic. These are primarily
catalyzed by CYP450 enzymes. Glucuronidation (A) and acetylation (B) are Phase II
conjugation reactions.
9. A patient with renal impairment (eGFR < 30 mL/min) is prescribed a drug eliminated
primarily by renal excretion. What adjustment is necessary?
A. Increase the dose to compensate for loss.
B. Decrease the dose or increase the dosing interval.
C. Switch to IV administration.
D. Administer with food to enhance absorption.
Correct Answer: B
Rationale: Drugs eliminated renally accumulate in patients with kidney impairment due to
decreased clearance. To prevent toxicity, the dose must be reduced or the dosing interval
WGU D116 Advanced Pharmacology Final Exam
Actual Exam 2026/2027 – Complete Exam-Style
Questions with Detailed Rationales | 100%
Verified | Pass Guaranteed – A+ Graded
[SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS]
1. Which route of administration is most affected by the first-pass effect, resulting in
significantly lower bioavailability of the drug?
A. Sublingual.
B. Intravenous.
C. Oral.
D. Transdermal.
Correct Answer: C
Rationale: Oral administration exposes drugs to the acidic environment of the stomach and the
hepatic portal system before they reach systemic circulation. This "first-pass metabolism" by the
liver metabolizes a significant portion of the drug, lowering the bioavailability. Intravenous (B)
bypasses this entirely, and sublingual (A) and transdermal (D) routes enter the systemic
circulation directly via capillaries, avoiding significant first-pass metabolism.
2. A drug with a high volume of distribution (Vd) is most likely to have which characteristic?
A. Low concentration in tissues.
B. High concentration in plasma.
C. Extensive distribution into body tissues.
D. Low lipid solubility.
Correct Answer: C
Rationale: Volume of distribution (Vd) is a theoretical volume that relates the amount of drug in
the body to its plasma concentration. A high Vd indicates that the drug is extensively distributed
,2
into body tissues (often due to high lipid solubility) rather than remaining in the plasma. Drugs
with high Vd are often highly protein-bound and lipophilic.
3. A patient taking a highly protein-bound drug (e.g., warfarin) is prescribed a second drug that
displaces it from albumin. What is the clinical result?
A. Increased free drug concentration and risk of toxicity.
B. Decreased free drug concentration and risk of subtherapeutic effect.
C. Increased metabolism of the drug by the liver.
D. Rapid elimination by the kidneys.
Correct Answer: A
Rationale: Protein-bound drugs exist in equilibrium with free (active) drug. If a second drug
displaces the first from binding sites (e.g., albumin), the concentration of free, pharmacologically
active drug increases suddenly. This can lead to toxicity, as the body is suddenly exposed to a
higher level of active drug.
4. Which Cytochrome P450 (CYP) enzyme is responsible for the metabolism of the largest
percentage of drugs?
A. CYP2D6.
B. CYP3A4.
C. CYP2C9.
D. CYP1A2.
Correct Answer: B
Rationale: CYP3A4 is the most abundant CYP enzyme in the liver and is responsible for
metabolizing approximately 50% of currently available drugs. It is also highly susceptible to
induction (by St. John's Wort) and inhibition (by grapefruit juice), leading to significant drug
interactions.
,3
5. A patient is taking theophylline for COPD. They start taking ciprofloxacin, a CYP1A2
inhibitor. What adjustment is needed?
A. Increase theophylline dose.
B. Decrease theophylline dose.
C. No change needed.
D. Switch to inhaled corticosteroids.
Correct Answer: B
Rationale: Theophylline is primarily metabolized by CYP1A2. Ciprofloxacin is a strong
CYP1A2 inhibitor, which will decrease the clearance of theophylline, leading to elevated serum
levels and potential toxicity (nausea, seizures). Therefore, the dose of theophylline must be
decreased to prevent toxicity.
6. Which drug has the narrowest therapeutic index, requiring careful monitoring to avoid
toxicity?
A. Penicillin VK.
B. Amlodipine.
C. Digoxin.
D. Ibuprofen.
Correct Answer: C
Rationale: Digoxin has a narrow therapeutic index, meaning the difference between a therapeutic
dose and a toxic dose is very small. Small increases in serum levels can lead to life-threatening
arrhythmias or visual changes, necessitating close monitoring of serum digoxin levels. Penicillin
(A) and ibuprofen (D) have wide safety margins.
7. A partial agonist differs from a full agonist in that a partial agonist:
A. Has higher efficacy than a full agonist.
B. Binds to the same receptor but produces a submaximal response.
C. Binds to a different receptor site.
, 4
D. Produces a response only in the presence of an endogenous ligand.
Correct Answer: B
Rationale: A partial agonist binds to the same receptor as a full agonist but has lower intrinsic
efficacy. Even at full receptor occupancy, it cannot produce the maximal response (Emax) that a
full agonist can, effectively acting as an antagonist in the presence of a full agonist.
8. Which Phase I reaction involves oxidative reactions (oxidation, reduction, hydrolysis)
primarily mediated by CYP450 enzymes?
A. Glucuronidation.
B. Acetylation.
C. Sulfation.
D. Oxidation.
Correct Answer: D
Rationale: Phase I reactions modify the drug chemically through oxidation, reduction, or
hydrolysis to expose or add a functional group, making it more hydrophilic. These are primarily
catalyzed by CYP450 enzymes. Glucuronidation (A) and acetylation (B) are Phase II
conjugation reactions.
9. A patient with renal impairment (eGFR < 30 mL/min) is prescribed a drug eliminated
primarily by renal excretion. What adjustment is necessary?
A. Increase the dose to compensate for loss.
B. Decrease the dose or increase the dosing interval.
C. Switch to IV administration.
D. Administer with food to enhance absorption.
Correct Answer: B
Rationale: Drugs eliminated renally accumulate in patients with kidney impairment due to
decreased clearance. To prevent toxicity, the dose must be reduced or the dosing interval
